The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation
- PMID: 37151808
- PMCID: PMC10161310
- DOI: 10.1177/20406207231170708
The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation
Abstract
Background: Umbilical cord blood hematopoietic stem cells are commonly used for hematopoietic system reconstitution in recipients after umbilical cord blood transplantation (UCBT). However, the optimal conditioning regimen for UCBT remains a topic of debate. The exact impact of total body irradiation (TBI) as a part of conditioning regimens remains unknown.
Objectives: The aim of this study was to evaluate the impacts of TBI on UCBT outcomes.
Design: This was a multi-institution retrospective study.
Methods: A retrospective analysis was conducted on the outcomes of 136 patients receiving UCBT. Sixty-nine patients received myeloablative conditioning (MAC), in which 33 underwent TBI and 36 did not, and 67 patients received reduced-intensity conditioning (RIC), in which 43 underwent TBI and 24 did not. Univariate and multivariate analyses were conducted to compare the outcomes and the post-transplant complications between patients who did and did not undergo TBI in the MAC subgroup and RIC subgroup, respectively.
Results: In the RIC subgroup, patients who underwent TBI had superior overall survival (adjusted hazard ratio [aHR] = 0.25, 95% confidence interval [CI]: 0.09-0.66, p = 0.005) and progression-free survival (aHR = 0.26, 95% CI: 0.10-0.66, p = 0.005). However, in the MAC subgroup, there were no statistically significant differences between those receiving and not receiving TBI.
Conclusion: In the setting of RIC in UCBT, TBI utilization can improve overall survival and progression-free survival. However, TBI does not show superiority in the MAC setting.
Keywords: Myeloablative considition; post cord blood hematological stem cell transplant outcome; reduced-intensity condition; total body irradiation; umbilical cord blood hematopoietic stem cell transplantation.
© The Author(s), 2023.
Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures





References
-
- Kurtzberg J, Laughlin M, Graham ML, et al.. Placental blood as a source of hematopoietic stem cells for transplantation in unrelated recipients. N Engl J Med 1996; 335: 157–166. - PubMed
-
- Wagner JE, Rosenthal J, Sweetman R, et al.. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996; 88: 795–802. - PubMed
-
- Rubinstein P, Taylor PE, Scaradavou A, et al.. Unrelated placental blood for bone marrow reconstitution: organization of the placental blood program. Blood Cells 1994; 20: 587–596; discussion 596–600. - PubMed
-
- Barker JN, Weisdorf DJ, DeFor TE, et al.. Transplantation of two partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 108: 1343–1347. - PubMed
-
- Barker JN, Krepski TP, DeFor TE, et al.. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant 2002; 8: 257–260. - PubMed
LinkOut - more resources
Full Text Sources